Clinics in Dermatology
Volume 24, Issue 3 , Pages 213-221 , May 2006

Loxoscelism

  • David L. Swanson, MD

      Affiliations

    • Department of Dermatology, Mayo Clinic, Scottsdale, AZ 85259, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 480 301 6174.
    • ,
  • Richard S. Vetter, MS

      Affiliations

    • Department of Entomology, University of California Riverside, Riverside, CA 92521, USA

References 

  1. Binford GJ, Wells MA. The phylogenetic distribution of sphingomyelinase D activity in venoms of haplogyne spiders. Comp Biochem Physiol B Biochem Mol Biol. 2003;135:25–33
  2. Caveness WA. Insect bite, complicated with fever. Nashville J Med Surg. 1872;10:333–337
  3. Macchiavello A. Cutaneous arachnidism or gangrenous spot of Chile. P R J Public Health Trop Med. 1947;22:425–466
  4. Schmaus LF. Case of arachnidism (spider bite). JAMA. 1929;92:1265–1266
  5. Atkins JA, Curtis WW, Sodeman WA. Probable cause of necrotic spider bite in the Midwest. Science. 1957;126:73
  6. Platnick NI. The World Spider Catalogue, Version 6.0. http://research.amnh.org/entomology/spiders/catalog/INTRO1.html2005;
  7. Gertsch WJ, Ennik F. The spider genus Loxosceles in North America, Central America and the West Indies (Araneae Loxoscelidae). Bull Am Mus Nat Hist. 1983;175:264–360
  8. Vetter RS. Arachnids submitted as suspected brown recluse spiders (Araneae: Sicariidae): Loxosceles spiders are virtually restricted to their known distributions but are perceived to exist throughout the United States. J Med Entomol. 2005;42:512–521
  9. Vetter RS, Edwards GB, James LF. Reports of envenomation by brown recluse spiders (Araneae: Sicariidae) outnumber verifications of Loxosceles spiders in Florida. J Med Entomol. 2004;41:593–597
  10. White J, Cardoso JL, Fan HW. Clinical toxicology of spider bites. Ch. 20. In:  Meier J,  White J editor. Handbook of clinical toxicology of animal venoms and poisons. Boca Raton (Fla): CRC Press; 1995;p. 261–329
  11. Gertsch WJ. The spider genus Loxosceles in South America (Araneae Scytodidae). Bull Am Mus Nat Hist. 1967;136:117–174
  12. Van Den Berg CW, De Andrade RM, Magnoli FC, Marchbank KJ, Tambourgi DV. Loxosceles spider venom induces metalloproteinase mediated cleavage of MCP/CD46 and MHCI and induces protection against C-mediated lysis. Immunology. 2002;107:102–110
  13. Futrell JM. Loxoscelism. Am J Med Sci. 1992;304:261–267
  14. Southcott RV. Spiders of the genus Loxosceles in Australia. Med J Aust. 1976;1:406–408
  15. Fischer ML, Vasconcellos-Neto J. Microhabitats occupied by Loxosceles intermedia and Loxosceles laeta (Araneae:Sicariidae) in Curitiba, Parana, Brazil. J Med Entomol. 2005;42:756–765
  16. Schenone H, Rojas A, Reyes H, Villarroel F, Suarez G. Prevalence of Loxosceles laeta in houses in central Chile. Am J Trop Med Hyg. 1970;19:564–567
  17. Vetter R. Identifying and misidentifying the brown recluse spider. http://dermatology.cdlib.org/DOJvol5num2/special/recluse.html[Last accessed 9/28/05]
  18. Brescovit AD, Rheims CA. On the synanthropic species of the genus Scytodes Latreille (Araneae, Scytodidae) of Brazil, with synonymies and records of these species in other neotropical countries. Bull Br Arachnol Soc. 2000;11:320–330
  19. Isbister GK, Gray MR. White-tail spider bite: a prospective study of 130 definite bites by Lampona species. Med J Aust. 2003;179:199–202
  20. Ribeiro LA, Jorge MT, Piesco RV, Nishioka S de A. Wolf spider bites in Sao Paulo, Brazil: a clinical and epidemiological study of 515 cases. Toxicon. 1990;28:715–717
  21. Isbister GK, Framenau VW. Australian wolf spider bites (Lycosidae): clinical effects and influence of species on bite circumstances. J Toxicol Clin Toxicol. 2004;42:153–161
  22. Isbister GK, Gray MR. Black house spiders are unlikely culprits in necrotic arachnidism: a prospective study. Intern Med J. 2004;34:287–289
  23. Vetter RS, Isbister GK. Do hobo spider bites cause dermonecrotic injuries?. Ann Emerg Med. 2004;44:605–607
  24. Young AR, Pincus SJ. Comparison of enzymatic activity from three species of necrotising arachnids in Australia: Loxosceles rufescens, Badumna insignis and Lampona cylindrata. Toxicon. 2000;39:391–400
  25. Foradori MJ, Smith SC, Smith E, Wells RE. Survey for potentially necrotizing spider venoms, with special emphasis on Cheiracanthium mildei. Comp Biochem Physiol C Toxicol Pharmacol. 2005;141:32–39
  26. Isbister GK. Letter to the editor. Toxicon. 2001;39:1941–1942
  27. Bodner MR, Callahan M, Binford GJ. Evolutionary origin and loss of sphingomyelinase D in the Sicarius and Loxosceles lineages. In: 29th Annual meeting of Amer. Arachnol. Soc. Akron OH, 29 Jun. 2005;
  28. Macchiavello A. Cutaneous arachnidism experimentally produced with the glandular poison of Loxosceles laeta. P R J Public Health Trop Med. 1948;23:266
  29. da Silva PH, da Silveira RB, Appel MH, et al. Brown spiders and loxoscelism. Toxicon. 2004;44:693–709
  30. de Oliveira KC, Goncalves de Andrade RM, Piazza RM, et al. Variations in Loxosceles spider venom composition and toxicity contribute to the severity of envenomation. Toxicon. 2005;45:421–429
  31. Morgan PN. Preliminary studies on venom from brown recluse spider, Loxosceles reclusa. Toxicon. 1969;6:161–165
  32. Wigger E, Kuhn-Nentwig L, Nentwig W. The venom optimisation hypothesis: a spider injects large venom quantities only into difficult prey types. Toxicon. 2002;40:749–752
  33. da Silveira RB, dos Santos Filho JF, Mangili OC, et al. Identification of proteases in the extract of venom glands from brown spiders. Toxicon. 2002;40:815–822
  34. Fernandes PMF, Junqueira de Azevedo IL, Goncalves de Andrade RM, et al. Molecular cloning and expression of a functional dermonecrotic and haemolytic factor from Loxosceles laeta venom. Biochem Biophys Res Commun. 2002;298:638–645
  35. Kalapothakis E, Araujo SC, de Castro CS, et al. Molecular cloning, expression and immunological properties of LiD1, a protein from the dermonecrotic family of Loxosceles intermedia spider venom. Toxicon. 2002;40:1691–1699
  36. Guilherme P, Fernandes I, Barbaro KC. Neutralization of dermonecrotic and lethal activities and differences among 32-35 kDa toxins of medically important Loxosceles spider venoms in Brazil revealed by monoclonal antibodies. Toxicon. 2001;39:1333–1342
  37. Norment BR, Jong YS, Heitz JR. Separation and characterization of venom components in Loxosceles reclusa-III. Hydrolytic enzyme activity. Toxicon. 1979;17:539–548
  38. Schenone H, Suarez G. Venoms of Scytodidae. Genus Loxosceles. In:  Bettini S editors. Handbook of experimental pharmacology. Arthropod venoms. vol. 48:New York: Springer-Verlag; 1978;p. 247–275
  39. Forrester LJ, Barrett JT, Campbell BJ. Red blood cell lysis induced by the venom of the brown recluse spider: The role of sphingomyelinase D. Arch Biochem Biophys. 1978;187:355–365
  40. Russell FE. Phosphodiesterase of some snake and arthropod venoms. Toxicon. 1966;4:153–154
  41. Jong YS, Norment BR, Heitz JR. Separation and characterization of venom components in Loxosceles reclusa-II. Protease enzyme activity. Toxicon. 1979;17:529–537
  42. Feitosa L, Gremski W, Veiga SS, et al. Detection and characterization of metalloproteinases with gelatinolytic, fibronectinolytic and fibrinogenolytic activities in brown spider (Loxosceles intermedia) venom. Toxicon. 1998;36:1039–1051
  43. Veiga SS, Feitosa L, dos Santos VL, et al. Effect of brown spider venom on basement membrane structures. Histochem J. 2000;32:397–408
  44. Rekow MA, Civello DJ, Geren CR. Enzymatic and hemolytic properties of brown recluse spider (Loxosceles reclusa) toxin and extracts of venom apparatus, cephalothorax and abdomen. Toxicon. 1983;29:1225–1233
  45. Veiga SS, da Silveira RB, Dreyfus JL, et al. Identification of high molecular weight serine-proteases in Loxosceles intermedia (brown spider) venom. Toxicon. 2000;38:825–839
  46. Tambourgi DV, Morgan BP, de Andrade RM, Magnoli FC, van Den Berg CW. Loxosceles intermedia spider envenomation induces activation of an endogenous metalloproteinase, resulting in cleavage of glycophorins from the erythrocyte surface and facilitating complement-mediated lysis. Blood. 2000;95:683–691
  47. Tambourgi DV, Magnoli FC, Von Eickstedt VR, et al. Incorporation of a 35-kilodalton purified protein from Loxosceles intermedia spider venom transforms human erythrocytes into activators of autologous complement alternative pathway. J Immunol. 1995;155:4459–4466
  48. Foradori MJ, Keil LM, Wells RE, Diem M, Tillinghast EK. An examination of the potential role of spider digestive proteases as a causative factor in spider bite necrosis. Comp Biochem Physiol C. 2001;130:209–218
  49. Monteiro CL, Rubel R, Cogo LL, et al. Isolation and identification of Clostridium perfringens in the venom and fangs of Loxosceles intermedia (brown spider): enhancement of the dermonecrotic lesion in loxoscelism. Toxicon. 2002;40:409–418
  50. Vetter RS, Barger DK. An infestation of 2055 brown recluse spiders (Araneae: Sicariidae) and no envenomations in a Kansas home: implications for bite diagnoses in nonendemic areas. J Med Entomol. 2002;39:948–951
  51. Berger RS. The unremarkable brown recluse spider bite. JAMA. 1973;225:1109–1110
  52. Gomez HF, Krywko DM, Stoecker WV. A new assay for the detection of Loxosceles species (brown recluse) spider venom. Ann Emerg Med. 2002;39:469–474
  53. Anderson PC. Loxoscelism threatening pregnancy: five cases. Am J Obstet Gynecol. 1991;165:1454–1456
  54. Franca FO, Barbaro KC, Abdulkader RC. Rhabdomyolysis in presumed viscero-cutaneous loxoscelism: report of two cases. Trans R Soc Trop Med Hyg. 2002;96:287–290
  55. Anderson PC. Missouri brown recluse spider: a review and update. Mo Med. 1998;95:318–322
  56. Veiga SS, Zanetti VC, Franco CR, et al. In vivo and in vitro cytotoxicity of brown spider venom for blood vessel endothelial cells. Thromb Res. 2001;102:229–237
  57. Ospedal KZ, Appel MH, Fillus Neto J, et al. Histopathological findings in rabbits after experimental acute exposure to the Loxosceles intermedia (brown spider) venom. Int J Exp Pathol. 2002;83:287–294
  58. Smith CW, Micks DW. The role of polymorphonuclear leukocytes in the lesion caused by the venom of the brown spider, Loxosceles reclusa. Lab Invest. 1970;22:90–93
  59. Tambourgi DV, Paixao-Cavalcante D, Goncalves de Andrade RM, et al. Loxosceles sphingomyelinase induces complement-dependent dermonecrosis, neutrophil infiltration, and endogenous gelatinase expression. J Invest Dermatol. 2005;124:725–731
  60. Ward PA, Cochrane CG. Bound complement and immunologic injury of blood vessels. J Exp Med. 1965;121:215–234
  61. Gates CA, Rees RS. Serum amyloid P component: its role in platelet activation stimulated by sphingomyelinase D purified from the venom of the brown recluse spider (Loxosceles reclusa). Toxicon. 1990;28:1303–1315
  62. Rees RS. Platelet activation stimulated by the toxin of the brown recluse spider requires serum amyloid P component, not C-reactive protein. Toxicon. 1989;27:953–954
  63. Veiga SS, Zanetti VC, Braz A, Mangili OC, Gremski W. Extracellular matrix molecules as targets for brown spider venom toxins. Braz J Med Biol Res. 2001;34:843–850
  64. Sutherland SK. Venoms of Dipluridae. In:  Bettini S editors. Handbook of experimental pharmacology. Arthropod venoms. vol. 48:New York: Springer-Verlag; 1978;p. 121–148
  65. Swanson DL, Vetter RS. Bites of brown recluse spiders and suspected necrotic arachnidism. N Engl J Med. 2005;352:700–707
  66. Vetter RS, Cushing PE, Crawford RL, Royce LA. Diagnoses of brown recluse spider bites (loxoscelism) greatly outnumber actual verifications of the spider in four western American states. Toxicon. 2003;42:413–418
  67. Russell FE, Gertsch WJ. Letter to the editor. Toxicon. 1983;21:337–339
  68. Moaven LD, Alten SA, Newnham AR. Sporotrichosis mimicking necrotising arachnidism. Med J Aust. 1999;171:685–686
  69. Osterhoudt KC, Zaoutis T, Zorc JJ. Lyme disease masquerading as brown recluse spider bite. Ann Emerg Med. 2002;39:558–561
  70. Roche KJ, Chang MW, Lazarus H. Cutaneous anthrax infection. N Engl J Med. 2001;345:1611
  71. Dominguez TJ. It's not a spider bite, it's community-acquired methicillin-resistant Staphylococcus aureus. J Am Board Fam Pract. 2004;17:220–226
  72. Beilman GJ, Sandifer G, Skarda D, et al. Emerging infections with community-associated methicillin-resistant Staphylococcus aureus in outpatients at an Army Community Hospital. Surg Infect (Larchmt). 2005;6:87–92
  73. Auer AI, Hershey FB. Surgery for necrotic bites of the brown spider. Arch Surg. 1974;108:612–618
  74. Fardon DW, Wingo CW, Robinson DW, Masters FW. The treatment of brown spider bite. Plast Reconstr Surg. 1967;40:482–488
  75. Paniker U, Levine N. Dapsone and sulfapyridine. Dermatol Clin. 2001;19:79–86
  76. King LE, Rees RS. Dapsone treatment of a brown recluse bite. JAMA. 1983;250:648
  77. Barrett SM, Romine-Jenkins M, Fisher DE. Dapsone or electric shock therapy of brown recluse spider envenomation?. Ann Emerg Med. 1994;24:21–25
  78. Phillips S, Kohn M, Baker D, et al. Therapy of brown spider envenomation: a controlled trial of hyperbaric oxygen, dapsone, and cyproheptadine. Ann Emerg Med. 1995;25:363–368
  79. Elston DM, Miller SD, Young RJ, et al. Comparison of colchicine, dapsone, triamcinolone, and diphenhydramine therapy for the treatment of brown recluse spider envenomation: a double-blind, controlled study in a rabbit model. Arch Dermatol. 2005;141:595–597
  80. Bryant SM, Pittman LM. Dapsone use in Loxosceles reclusa envenomation: is there an indication?. Am J Emerg Med. 2003;21:89–90
  81. Gleid R, Rico J. Treatment of autoimmune blistering diseases. Dermatol Clin. 1999;17:431–440
  82. Dillaha CJ, Jansen GT, Honeycutt WM, Hayden CR. The gangrenous bite of the brown spider in Arkansas. J Ark Med Soc. 1963;60:91
  83. Jansen GT, Morgan PN, McQueen JN, Bennett WE. The brown recluse spider bite: controlled evaluation of treatment using the white rabbit as an animal model. South Med J. 1971;62:1194–1202
  84. Maynor ML, Moon RE, Klitzman B, Fracica PJ, Canada A. Brown recluse spider bites: beneficial effects of hyperbaric oxygen. J Hyperb Med. 1992;7:89–102
  85. Svendsen FJ. Treatment of clinically diagnosed brown recluse spider bites with hyperbaric oxygen: a clinical observation. J Ark Med Soc. 1986;83:199–204
  86. Hobbs GD, Anderson AR, Greene TJ, Yealy DM. Comparison of hyperbaric oxygen and dapsone therapy for Loxosceles envenomation. Acad Emerg Med. 1996;3:758–761
  87. Guderian RH, Mackenzie CD, Williams JF. High voltage shock treatment for snake bite. Lancet. 1986;2:229
  88. Osborn CD. Treatment of spider bites by high voltage direct current. J Okla State Med Assoc. 1991;84:257–260
  89. Rees RS, Altenbern DP, Lynch JB, King LE. Brown recluse spider bites. A comparison of early surgical excision versus dapsone and delayed surgical excision. Ann Surg. 1985;202:659–663
  90. Malaque CM, Castro-Valencia JE, Cardoso JL, et al. Clinical and epidemiological features of definitive and presumed loxoscelism in Sao Paulo, Brazil. Rev Inst Med Trop Sao Paulo. 2002;44:139–143
  91. de Roodt AR, Litwin S, Dokmetjian JC, Vidal JC. A reduced immunization scheme to obtain an experimental anti-Loxosceles laeta (“violinist spider”) venom. J Nat Toxins. 2002;11:193–203
  92. Barbaro KC, Knysak I, Martins R, Hogan C, Winkel K. Enzymatic characterization, antigenic cross-reactivity and neutralization of dermonecrotic activity of five Loxosceles spider venoms of medical importance in the Americas. Toxicon. 2005;45:489–499
  93. Rees R, Campbell D, Rieger E, King LE. The diagnosis and treatment of brown recluse spider bites. Ann Emerg Med. 1987;16:945–949
  94. Araujo SC, Castanheira P, Alvarenga LM, et al. Protection against dermonecrotic and lethal activities of Loxosceles intermedia spider venom by immunization with a fused recombinant protein. Toxicon. 2003;41:261–267

PII: S0738-081X(05)00172-0

doi: 10.1016/j.clindermatol.2005.11.006

Clinics in Dermatology
Volume 24, Issue 3 , Pages 213-221 , May 2006

Article Tools

* Image Usage & Resolution